AI Analysis AI Analysis of CLLS
Powered by GPT-4o
Stock Analysis
Risk Assessment
Trading Strategy
PDF

Cellectis S.A. stock price down 1.21% on Monday
(Updated on Mar 17, 2025)

Sell candidate since Jan 10, 2025 Loss -33.78%

The Cellectis S.A. stock price fell by -1.21% on the last day (Monday, 17th Mar 2025) from $1.24 to $1.23. It has now fallen 3 days in a row. During the last trading day the stock fluctuated 3.39% from a day low at $1.19 to a day high of $1.23. The price has fallen in 6 of the last 10 days and is down by -5.04% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -13 million shares and in total, 536 thousand shares were bought and sold for approximately $656.51 thousand.

The stock lies in the lower of a very wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $1.16 is broken, it will firstly indicate a stronger fall rate. Given the current short-term trend, the stock is expected to fall -22.49% during the next 3 months and, with a 90% probability hold a price between $0.90 and $1.34 at the end of this 3-month period.

Investment opportunities can be found at any hour. So, react immediately to market-moving news and capture more market opportunities when convenient for you. You can trade over 10,000 US Stocks and ETFs, US Equity Index options, US Treasuries – and more - around the clock . Interactive Brokers’ dual market centers ensure reliable and dependable overnight trading on your timetable. (Member SIPC)
IBKR Logo

CLLS Signals & Forecast

A buy signal was issued from a pivot bottom point on Thursday, March 06, 2025, and so far it has risen 0.410%. Further rise is indicated until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Cellectis S.A. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $1.25 and $1.44. A break-up above any of these levels will issue buy signals. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.

Support, Risk & Stop-loss for Cellectis S.A. stock

Cellectis S.A. finds support from accumulated volume at $1.22 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.0404 between high and low, or 3.39%. For the last week the stock has had daily average volatility of 8.81%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (CLLS) For The Upcoming Trading Day Of Tuesday 18th

For the upcoming trading day on Tuesday, 18th we expect Cellectis S.A. to open at $1.22, and during the day (based on 14 day Average True Range), to move between $1.13 and $1.32, which gives a possible trading interval of +/-$0.0972 (+/-7.93%) up or down from last closing price. If Cellectis S.A. takes out the full calculated possible swing range there will be an estimated 15.86% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $1.22 (0.41%) than the resistance at $1.24 (1.22%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Cellectis S.A. stock A Buy?

Cellectis S.A. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -4.235 Sell Candidate Unchanged

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

Predicted Fair Opening Price

Predicted fair opening price on March 18, 2025 - $1.22 ( 0.81%).

CLLS Performance

Trading levels for CLLS

Fibonacci Support & Resistance Levels

Level Price
R3 1.26 2.49%
R2 1.24 1.23%
R1 1.23 0.454%
Price 1.23
S1 1.20 -2.07%
S2 1.19 -2.84%
S3 1.17 -4.10%

Accumulated Volume Support & Resistance Levels

Level Price
R3 1.51 23.27%
R2 1.29 5.31%
R1 1.24 1.22%
Price 1.23
S1 1.22 -0.408%
S2 0 -
S3 0 -

FAQ

What is the symbol for Cellectis S.A. Stock and on which exchange is it traded?
The symbol for Cellectis S.A. is CLLS and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Cellectis S.A. Stock?
Cellectis S.A. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy Cellectis S.A. Stock?
Cellectis S.A. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Cellectis S.A. Stock.

What's the current price of Cellectis S.A. Stock?
As of the end of day on the Mar 17, 2025, the price of an Cellectis S.A. (CLLS) share was $1.23.

What is the 52-week high and low for Cellectis S.A. Stock?
The 52-week high for Cellectis S.A. Stock is $3.38 and the 52-week low is $1.14.

What is the market capitalization of Cellectis S.A. Stock?
As of the Mar 17, 2025, the market capitalization of Cellectis S.A. is 122.615M.

When is the next earnings date for Cellectis S.A.?
The upcoming earnings date for Cellectis S.A. is May 05, 2025.
Click to get the best stock tips daily for free!
ABOUT CELLECTIS S.A.
Cellectis S.A.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALL...
GOLDEN STAR
Ticker Change Signal Date
DESP
$19.20
0.260% Mar 13
AMED
$92.59
0.0540% Mar 13
O
ODD
$44.71
4.18% Mar 13
ALE
$65.32
0.138% Mar 12
HESM
$40.63
6.25% Mar 11

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE